Suh Minseok, Park Hyo Jin, Choi Hyoung Soo, So Young, Lee Byung Chul, Lee Won Woo
Departments of Nuclear Medicine.
Pathology, and.
Pediatrics. 2014 Dec;134(6):e1731-4. doi: 10.1542/peds.2014-1872.
The use of an (18)F-labeled radiopharmaceutical for positron emission tomography (PET) imaging of sympathetic neuronal activity has a tremendous clinical impact because it circumvents the substantial drawbacks of the prototypical imaging agent, (123)I-metaiodobenzylguanidine (MIBG). We describe a 14-year-old male patient who had neuroblastoma and underwent (18)F-fluoropropylbenzylguanidine (FPBG) PET/computed tomography (CT). We compared the findings of (18)F-FPBG PET/CT with those of (123)I-MIBG γ scintigraphy. (18)F-FPBG PET/CT readily demonstrated a focal lesion in the left tibia, but the lesion was not seen using (123)I-MIBG scintigraphy. Surgical resection proved the presence of a neuroblastoma lesion in the left tibia. To the best of our knowledge, our study was the first to use an (18)F-labeled radiopharmaceutical for evaluating sympathetic neuronal activity in neuroblastoma. We suggest that (18)F-FPBG is a promising PET agent for imaging sympathetic neuronal activity in neuroblastoma.
使用（18）F标记的放射性药物进行交感神经活动的正电子发射断层扫描（PET）成像具有巨大的临床意义，因为它克服了典型成像剂（123）I-间碘苄胍（MIBG）的诸多重大缺点。我们描述了一名患有神经母细胞瘤的14岁男性患者，其接受了（18）F-氟丙基苄胍（FPBG）PET/计算机断层扫描（CT）检查。我们将（18）F-FPBG PET/CT的检查结果与（123）I-MIBGγ闪烁显像的结果进行了比较。（18）F-FPBG PET/CT很容易显示出左胫骨的一个局灶性病变，但（123）I-MIBG闪烁显像未发现该病变。手术切除证实左胫骨存在神经母细胞瘤病变。据我们所知，我们的研究是首次使用（18）F标记的放射性药物评估神经母细胞瘤中的交感神经活动。我们认为（18）F-FPBG是一种用于神经母细胞瘤交感神经活动成像的有前景的PET剂。
Zotero 插件